Sign In
Buy ILMN
$205.10
+0.0100 (+0.0049%)
At Close: Jul 31, 2026
Illumina says it had expected EU hold order on Grail
02:39pm, Monday, 20'th Sep 2021
U.S. life sciences company Illumina said on Monday that it had anticipated an order from EU antitrust enforcers to keep recently acquired Grail as a separate company while waiting for regulatory clear
The 1 Stock I'd Buy Right Now
07:05am, Saturday, 18'th Sep 2021
The pandemic isn't over yet.
5 Medtech Stocks to Seize Major Growth
03:26pm, Wednesday, 15'th Sep 2021
The merging of healthcare and technology is changing how we care for our bodies. It's also creating investment opportunities, such as these five medical technology stocks.
Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle
09:15am, Wednesday, 15'th Sep 2021
SAN DIEGO, Sept. 15, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has selected seven new genomics companies to join the third global funding cycle of Illumina Accelerator.
Illumina, Inc. (ILMN) CEO Francis deSouza Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)
07:19pm, Monday, 13'th Sep 2021
Illumina, Inc. (ILMN) CEO Francis deSouza Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)
Illumina Commits to Net Zero Global Greenhouse Gas Emissions by 2050
09:30am, Thursday, 09'th Sep 2021
SAN DIEGO, Sept. 9, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) elevates climate action goals with commitments for net zero greenhouse gas emissions aligned with the Paris Agreement, commits to
Illumina (ILMN), Merck Ink Cancer Companion Diagnostics Deal
10:14am, Wednesday, 08'th Sep 2021
Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.
Illumina, Merck Join Hands For Homologous Recombination Deficiency CDx, Research Assay
10:38am, Tuesday, 07'th Sep 2021
Illumina Inc (NASDAQ: ILMN) and Merck & Co Inc (NYSE: MRK) provided more details on their partnership to develop and commercialize tests that gauge genetic mutations involved in homologous recomb
Why Illumina Wants Grail Back So Badly
09:55am, Saturday, 04'th Sep 2021
The gene-sequencing giant sees a huge opportunity in diagnostics.
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
05:30pm, Friday, 03'rd Sep 2021
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic R
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
07:30am, Friday, 03'rd Sep 2021
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic R
U.S. lawmakers question FTC's efforts to stop Illumina's deal for Grail
05:55pm, Thursday, 02'nd Sep 2021
Two Republican lawmakers on Thursday questioned the Federal Trade Commission's efforts to unwind life science company Illumina Inc's $7.1 billion acquisition of Grail Inc, alleging the regulator was n
3 Stocks These ESG Gurus Agree On
02:32pm, Thursday, 02'nd Sep 2021
Former Vice President Al Gore (Trades, Portfolio), leader of Generation Investment Management, and Jerome Dodson (Trades, Portfolio)'s Parnassus Investments may take slightly different approaches to i
Illumina To Webcast Upcoming Investor Conference
05:00pm, Monday, 30'th Aug 2021
SAN DIEGO, Aug. 30, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Morgan Stanley 19th Annual Global Heal
Will Illumina's Purchase of Grail Kill Cancer-Test Competition?
07:01pm, Friday, 27'th Aug 2021
Feds tell judge that the combined companies will unfairly monopolize the market for blood screening that can detect multiple cancers.
